Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting: ow.ly/XVSM50VH11Q $GNPX

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma: genprex.com/2025/04/28/gen… $GNPX

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting: ow.ly/bXmg50VJBQN $GNPX

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting: ow.ly/A94K50VKr1k $GNPX

Dr. Ismail Meraz presented this week at #AACR25 on Reqorsa® Gene for the treatment of KRASG12C mutant NSCLC. If you missed his presentation, find the poster here: ow.ly/zo9m50VM0Xl

Dr. Ismail Meraz and Genprex’s Chief Medical Officer, Mark Berger, pose for a photo at #AACR25. The team had a great week learning about the latest developments in cancer research. AACR

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma: ow.ly/rNew50VNFrz

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes: ow.ly/ccJa50VOmK9 $GNPX

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting: ow.ly/5gpn50W07aI

Genprex to Participate at BIO 2025 International Convention: ow.ly/uT2s50W4pz4

Dr. Bo Wang presented a poster on the Acclaim-3 clinical trial at #ASCO25 in the Trials in Progress portion of the conference. Visit our website to view the poster that was presented: ow.ly/nBOv50W4pI5 #genetherapy #oncology @bowangmd1

A study found that biomarker testing for patients with lung cancer is critical. $GNPX is continuing to discover and utilize biomarkers to select the patient populations most likely to respond to Reqorsa® Gene Therapy. Read more about the study: curetoday.com/view/biomarker…

$GNPX is pleased to have positive preclinical data presented on our novel #diabetes #genetherapy later this week at the ADA 85th Scientific Sessions. If you are attending the conference, stop by to hear our research collaborators share this exciting preclinical data #ADA2025

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions: ow.ly/GiV450WeGYs $GNPX

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions: ow.ly/bj5550WfrgS #ADA2025 #genetherapy #diabetes $GNPX

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update: genprex.com/2025/08/04/gen… $GNPX

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers: ow.ly/Eyjk50WHwkx

Last week Genprex issued a 2025 letter to stockholders, including several clinical updates. For more information on our oncology program and the program’s achievements in 2025, we encourage you to read the stockholder letter here: ow.ly/KeJh50WG4cv #Oncology #Genetherapy

$GNPX is passionate about our #diabetes program. We achieved several milestones in 2025 for our diabetes program. For a full overview of the program and more clinical updates, we encourage you to read our recent 2025 letter to stockholders here: ow.ly/NwW850WG4gZ

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences: ow.ly/lthL50WPwUp $GNPX